Cargando…
A Selective Small‐Molecule c‐Myc Degrader Potently Regresses Lethal c‐Myc Overexpressing Tumors
MYC oncogene is involved in the majority of human cancers and is often associated with poor outcomes, rendering it an extraordinarily desirable target, but therapeutic targeting of c‐Myc protein has been a challenge for >30 years. Here, WBC100, a novel oral active molecule glue that selectively d...
Autores principales: | Xu, Ying, Yu, Qingfeng, Wang, Ping, Wu, Zhaoxing, Zhang, Lei, Wu, Shuigao, Li, Mengyuan, Wu, Bowen, Li, Hongzhi, Zhuang, Haifeng, Zhang, Xuzhao, Huang, Yu, Gan, Xiaoxian, Xu, Rongzhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922104/ https://www.ncbi.nlm.nih.gov/pubmed/35048559 http://dx.doi.org/10.1002/advs.202104344 |
Ejemplares similares
-
Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis
por: Pelengaris, Stella, et al.
Publicado: (2004) -
C-myc and N-myc in the developing brain
por: Wey, Alice, et al.
Publicado: (2010) -
Activation of CaMKIIγ potentiates T-cell acute lymphoblastic leukemia leukemogenesis via phosphorylating FOXO3a
por: Jiang, Xudong, et al.
Publicado: (2017) -
Identification of the novel Np17 oncogene in human leukemia
por: Wu, Bowen, et al.
Publicado: (2020) -
Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)